Bioinfra Life Science Inc.

Bioinfra Inc.

Ho Sang Shin

Chul Woo Kim

Yong-Sung Shin

Kyung Nam Kang

Oh Ran Kwon

Yong Dai Kim

Eun Hee Yeon

Byoung-Kwon Kim

Yong Sung Shin

Kil Hyon Lee

Pil Je Park

A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model M by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data B; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model M; wherein the complex biomarker group includes CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.

Method for using information on complex biomarker group to diagnose lung cancer in a subject and diagnostic kit and computing system using the same

The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.

Method for monitoring, diagnosing, and screening cancer through measuring the concentration of des-R prothrombin activation peptide fragment F2 (des-R F2) in a serum

Growing community of inventors

Seoul, South Korea

Ho Sang Shin